Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse

PharmacoEconomics

Volumn 32, Issue 2, 2014, Pages 193-207

  Adena, Michael ^a   Houltram, Jennifer ^b,c   Mulligan, Stephen P ^d   Todd, Carlene ^e   Malanos, Grace ^e  

^a Datalytics Pty Ltd   (Australia)

^b Covance ^*  (Australia)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e Roche Products Pty Limited   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 84894042142     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-013-0125-7     Document Type: Article

References (30)

1. Eichhorst B, Hallek M, Dreyling M. Chronic lymphocytic leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):ii60-2.
2. Australian Institute of Health and Welfare (AIHW) 2012. ACIM (Australian Cancer Incidence and Mortality) Books. AIHW: Canberra. http://www.aihw.gov.au/ WorkArea/DownloadAsset.aspx?id=60129542437.
3. Kerridge I. Treatment of adult leukaemias. Aust Prescr. 2006;29(3):76-9.
4. Brugiatelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M, et al. Management of chronic lymphocytic leukemia: Practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2006;91(12):1662-73.
5. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: Arandomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.
6. Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756-65.
7. US National Comprehensive Cancer Network (NCCN). Clinical guidelines in oncology: Non-hodgkin's lymphomas V.12009.
8. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: Areport from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-56.
9. Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol. 2004;125(3):294-317.
10. Cancer Institute NSW (Australia). Chronic lymphocytic leukaemia treatment protocol. https://www.eviq.org.au/Protocol/tabid/66/id/496/view/FullView/ Chronic+Lymphocytic+Leukaemia+FCR+(Fludarabine+CYCLOPHOSPHamide+RITUximab).aspx.
11. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): Arandomised controlled trial. Lancet. 2007;370(9583):230-9.
12. Australian Government Actuary. Australian life tables. http://www.aga.gov.au/publications/.
13. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98(8):2319-25.
14. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793-8.
15. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885-91.
16. Australian Government Department of Health and Ageing (DoHA). Manual of resource items and their associated costs (2009). http://www.pbs.gov.au/ industry/useful-resources/manual/Manual%20of%20Resource%20Items%202009.pdf
17. Australian Government Department of Human Services. Medicare Australia statistics. 2009. https://www.medicareaustralia.gov.au/statistics/pbs-item. shtml.
18. Best L. Fludarabine in the treatment of chronic lymphocytic leukaemia. Bristol: Wessex Institute of Public Health. DEC report no. 441995.
19. Hancock S, Wake B, Hyde C. Fludarabine as first line therapy for chronic lymphocytic leukaemia. Birmingham: West Midlands Health Technology Assessment Collaboration (WMHTAC). DPHE report no. 422002.
20. Weeks JC, Tierney MR, Weinstein M. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med. 1991;325(2):81-6.
21. Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P. Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol. 2005;75(2):116-23.
22. Wild D, Walker M, Pettengell R, et al., editors. Utility elicitation in patients with follicular lymphoma. 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); Philadelphia: Value Health; 2006.
23. Beusterien KM, Davies J, Leach M, Meiklejohn D, Grinspan JL, O'Toole A, et al. Population preference values for treatment outcomes in chronic lymphocytic leukaemia: Across-sectional utility study. Health Qual Life Outcomes. 2010;18:8.
24. Harris A, Hill S, Chin G, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: Aretrospective analysis 1994-2004. Med Decision Mak. 2008;28(5):713-22.
25. Australian Government Department of Health. PBAC Public summary document. 2010. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd- rituximab-nov10.
26. Hornberger J, Reyes C, Shewade A, Lerner S, Friedmann M, Han L, et al. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(2):225-34.
27. Main C, Pitt M, Moxham T, Stein K. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: An evidence review of the submission from Roche. Health Technol Assess. 2010;14(Suppl. 2):27-32.
28. Dretzke J, Barton P, Kaambwa B, Connock M, Uthman O, Bayliss S, et al. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia. Health Technol Assess. 2010;14(Suppl. 2):19-26.
29. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011;117(11):3016-24.
30. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19(5):1414-20.